Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

BRAF-Mutated mCRC: Treating With the BEACON Regimen

April 23rd 2021

Gastrointestinal oncologists consider when it is most appropriate to initiate the BEACON trial regimen of encorafenib-binimetinib-cetuximab as treatment for BRAF-mutated metastatic colorectal cancer.

Dr. Wainberg on Optimal Dosing With Regorafenib in CRC

April 19th 2021

Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.

Treatments for BRAF-Mutated mCRC

April 16th 2021

Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.

Second-Line Treatment of mCRC: Rechallenging Therapy

April 16th 2021

The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.

Dr. Strickler on the Need for Chemotherapy-Free Options in Third-Line Metastatic CRC

April 14th 2021

John H. Strickler, MD, discusses the need for additional chemotherapy-free options in the third-line setting for patients with metastatic colorectal cancer.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis

April 13th 2021

The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.

Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC

April 13th 2021

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.

Atezolizumab Induces Durable Activity Irrespective of MSI Status in Advanced Solid Tumors With TMB ≥16 Mut/Mb

April 13th 2021

Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.

Tailoring Targeted Therapies in Metastatic CRC

April 13th 2021

Syed Kazmi, MD, highlights the go-to regimens for patients with mCRC.

FDA Authorizes Marketing of First AI Device to Detect Signs of Colon Cancer

April 12th 2021

The FDA has authorized the marketing of the first device that utilizes artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon in real time during a colonoscopy.

Preferences for Second-Line Therapy for mCRC

April 9th 2021

Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.

Maintenance Therapy for Metastatic CRC

April 9th 2021

Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.

Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRC

April 7th 2021

Atrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.

FDA Approves New Cetuximab Dose in KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck Cancer

April 7th 2021

The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

Dr. Dasari on Eligibility Criteria for the FRESCO-2 trial With Fruquintinib in CRC

April 5th 2021

Nageshwara Arvind Dasari, MD, discusses the eligibility criteria for the phase 3 FRESCO-2 trial, which examined the use of fruquintinib in patients with metastatic colorectal cancer.

ctDNA Scratches the Surface in Colorectal Cancer

April 5th 2021

Axel Grothey, MD, discusses the potential applications for ctDNA in CRC and shed light on the updated analysis from the pivotal IMbrave150 trial in advanced hepatocellular carcinoma.

Dr. Philip Spotlights Ongoing Research Efforts in CRC

April 2nd 2021

Tony Philip, MD, discusses research efforts underway in colorectal cancer.

DNX-2440 Shows Promise in CRC and Other Cancers With Liver Metastasis as Phase 1 Trial Begins

April 2nd 2021

Investigation into a novel oncolytic adenovirus as a treatment option for patients with colorectal cancer and other cancers with liver metastasis is underway.

Applying Aggressive Therapy to Treat mCRC Up Front

April 2nd 2021

The rationale for treating select patients with metastatic colorectal cancer with intensive therapy in the first-line setting vs waiting until disease progression.